From the Division of Trauma, Emergency Surgery, Critical Care, and Burns, Department of Surgery, University of Arizona, Tucson, Arizona.
J Trauma Acute Care Surg. 2014 Sep;77(3):417-21. doi: 10.1097/TA.0000000000000372.
Platelet dysfunction has been attributed to progression of initial intracranial hemorrhage (ICH) on repeat head computed tomographic (RHCT) scans in patients on prehospital antiplatelet therapy. However, there is little emphasis on the effect of platelet count and progression of ICH in patients with traumatic brain injury. The aim of this study was to determine the platelet count cutoff for progression on RHCT and neurosurgical intervention in patients on antiplatelet therapy.
We performed a prospective cohort analysis of all traumatic brain injury patients with an ICH on prehospital antiplatelet therapy. Antiplatelet therapy was defined as aspirin, clopidogrel, or a combination of both. Admission platelet count was recorded and used for analysis. Receiver operating characteristic curves were plotted to identify the optimal platelet count for progression on RHCT scan and neurosurgical intervention in patients on antiplatelet therapy.
A total of 264 patients were enrolled. Platelet count of 135,000/µL or less (area under the curve, 0.80) and platelet count of 95,000/µL or less (area under the curve, 0.92) were the optimal threshold points for progression on RHCT scan and neurosurgical intervention, respectively. Patients with platelet count of 135,000/µL or less were 12.4 times (95% confidence interval, 7.1-18.4) more likely to have progression on RHCT scan and patients with platelet count 95,000/µL or less were 31.5 times (95% confidence interval, 19.7-96.2) more likely to require neurosurgical intervention.
A platelet count of less than 135,000/µL in patients on antiplatelet therapy is predictive of both radiographic and clinical worsening. This is a clinically relevant target intended to help tailor and improve management in patients on antiplatelet therapy.
Therapeutic study, level III.
在接受院前抗血小板治疗的患者中,重复头部计算机断层扫描 (RHCT) 显示颅内出血 (ICH) 进展与血小板功能障碍有关。然而,对于创伤性脑损伤患者,血小板计数与 ICH 进展的关系并没有得到太多关注。本研究旨在确定接受抗血小板治疗的患者中 RHCT 和神经外科干预进展的血小板计数临界值。
我们对所有接受院前抗血小板治疗且 ICH 的创伤性脑损伤患者进行了前瞻性队列分析。抗血小板治疗定义为阿司匹林、氯吡格雷或两者的联合治疗。记录入院时的血小板计数并用于分析。绘制受试者工作特征曲线以确定接受抗血小板治疗的患者 RHCT 扫描和神经外科干预进展的最佳血小板计数。
共纳入 264 例患者。血小板计数 135,000/µL 或更低(曲线下面积,0.80)和血小板计数 95,000/µL 或更低(曲线下面积,0.92)分别是 RHCT 扫描和神经外科干预进展的最佳阈值点。血小板计数为 135,000/µL 或更低的患者在 RHCT 扫描上进展的可能性是血小板计数为 135,000/µL 或更高的患者的 12.4 倍(95%置信区间,7.1-18.4),血小板计数为 95,000/µL 或更低的患者需要神经外科干预的可能性是血小板计数为 95,000/µL 或更高的患者的 31.5 倍(95%置信区间,19.7-96.2)。
接受抗血小板治疗的患者血小板计数低于 135,000/µL 与影像学和临床恶化均相关。这是一个具有临床意义的目标,旨在帮助调整和改善接受抗血小板治疗的患者的管理。
治疗研究,III 级。